维普中文期刊产品整合服务
103篇 您的检索式:作者名="Gnjatic"
    题名 作者 年代 出处 被引量
1Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission 显示文摘Diefenbach CS Gnjatic S Sabbatini P 2008Clin Cancer Res2008,14,9:1
2Intraepithelial CDS+ tumor-infiltrating lymphocytes and a high CD8+/regnlatory T cell ratio are associated with favorable prognosis in ovarian cancer显示文摘Sato E Olson SH Ahn J Bundy B Nishikawa H Qian F Jungbluth AA Frosina D Gnjatic S Ambrosone C Kepner J Odunsi T Ritter G Lele S Chen YT Ohtani H Old LJ Odunsi K 2005Proc Natl Acad Sci USA2005,102,18:1
3Seromic analysis of anti-body responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays 显示文摘Gnjatic S Wheeler C Ebner M 2009J Immunol Methods2009,341,12:1
4Induction of primary NY-ESO-1 immunity: CD8^+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1^+ cancers 显示文摘Jager E Gnjatic S Nagata Y 2000Proc Natl Acad Sci USA2000,97,12:1
5The abscopal effectassociated with a systemic antimelanoma immune response 显示文摘Stamell EF Wolchok JD Gnjatic S 2013Int J Radiat Oncol Biol Phys2013,85,2:1
6NY-ESO-1 DNAvaccine induces T-cell responaes that 8re supp ressed by regulatory T cells显示文摘Gnjatic S Ahorki NK Tang DN 2009Clin CancerRes2009,15,6:1
7The abscopal effect associ- ated with a systemic anti-melanoma immune response显示文摘Stamell EF WolchokJD Gnjatic S 2013IntJ Ra- diat Oncol Biol Phys2013,85,2:1
8Monitoring CD8 T cell responses to NY-ESO-1 : correlation of humoral and cellular immune responses 显示文摘Jager E Nagata Y Gnjatic S 2000Proc Nat1 Acad Sci USA2000,97,:1
9Tumor-infiltrating NY-ESO-l-specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer显示文摘Matsuzaki J Gnjatic S Mhawech-Faueeglia P 2010Proc Natl Acad Sei U S A2010,107,17:1
10NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulator' T cells 显示文摘Gnjatic S Altorki NK Tang DN 2009Clin Cancer Res2009,15,6:1
11Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T cell epitope in a paticnt with bladder cancer显示文摘Sharma P Gnjatic S Jungbluth A A 2003Cancer Immun2003,3,:1
12Induction of primary NY-ESO-1 immunity:CD8^+ T lymphocyte and antibody responses in peptide vaccinated patients with NY-ESO-1^+ Cancers显示文摘Jager E Gnjatic S Nagata Y 2000Proc Natl Acad Sci USA2000,97,12:1
13NY-KSO-I : review of an immunogenic tumor antigen 显示文摘Gnjatic S Nishikawa H Jungbluth A A 2006Adv Cancer Res2006,95,:1
14Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients:correlation with antibody responses显示文摘Gnjatic S Atanackovic D Jager E 2003Proc Natl Acad Sci U S A2003,100,15:1
15Induction of primary NY-ESO-1 immunity:CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-eso-1+cancers显示文摘Jager E Gnjatic S Nagata Y 2000Proc Natl Acad Sci USA2000,97,12:1
16A induction of primary NYESO-1 immunity CD8^+ T lymphocyte and antibody response in peptide vaccinated patients with NY-ESO-I+ cancers显示文摘Jager E Gnjatic S Nagata Y 2000Proc Natl Acad Sci USA2000,97,12:1
17Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients显示文摘JagerE Karbach J Gnjatic S 2006Proc Natl Acad Sci USA2006,103,14:1
18Induction of p rimary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in pep tide2vaccinated patients with NY-ESO-1 + cancers显示文摘Jager E Gnjatic S Nagata Y 2000Proc Natl Acad Sci USA2000,97,12:1
19Induction of primary NY-ESO-1 immunity: CD8 + T lymphocyte and antibody responses in peptide- vaccinated patients with NY-ESO-1 + cancers 显示文摘Jager E Gnjatic S Nagata Y 2000Proc Natl Acad Sci USA2000,97,12:1
20Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma显示文摘Szmania S Gnjatic S Tricot G 2007Immunother2007,30,8:1
返回顶部 每页显示:
共6页 首页 上一页 第1页 下一页 末页 /6 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费